-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces It Is Investigating Claims Against Caribou Biosciences, Inc. and Encourages Investors With Losses to Contact the Firm
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces It Is Investigating Claims Against Caribou Biosciences, Inc. and Encourages Investors With Losses to Contact the Firm
Los Angeles, California--(Newsfile Corp. - December 26, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ: CRBU) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Caribou announced on December 12, 2022, "report[ing] new 12-month clinical data from cohort 1 in the ongoing ANTLER Phase 1 trial, which show long-term durability following a single infusion of CB-010 at the initial dose level 1 (40x106 CAR-T cells)." According to the Company, "3 of 6 patients maintained a durable CR [complete response] at 6 months," and "2 of 6 patients maintain a long-term CR at the 12 month scan and remain on the trial." Based on this news, shares of Caribou fell by more than 9% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at , or by email at bschall@schallfirm.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
To view the source version of this press release, please visit
Los Angeles, California--(Newsfile Corp. - December 26, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ: CRBU) for violations of the securities laws.
加利福尼亞州洛杉磯--(Newsfile Corp.-2022年12月26日)-全國性股東權利訴訟公司Schall律師事務所宣佈,它正在代表Cariou生物科學公司(“Cariou”或“公司”)(納斯達克:CRBU)的投資者調查違反證券法的索賠。
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Caribou announced on December 12, 2022, "report[ing] new 12-month clinical data from cohort 1 in the ongoing ANTLER Phase 1 trial, which show long-term durability following a single infusion of CB-010 at the initial dose level 1 (40x106 CAR-T cells)." According to the Company, "3 of 6 patients maintained a durable CR [complete response] at 6 months," and "2 of 6 patients maintain a long-term CR at the 12 month scan and remain on the trial." Based on this news, shares of Caribou fell by more than 9% on the same day.
調查的重點是該公司是否發佈了虛假和/或誤導性聲明和/或沒有披露與投資者相關的資訊。馴鹿於2022年12月12日宣佈[英]在正在進行的鹿角第一階段試驗中,來自隊列1的新的12個月臨床數據顯示,在以初始劑量水準1(40x106 CAR-T細胞)單次輸注CB-010後,這些數據顯示出長期的持久性。根據該公司的說法,6名患者中有3名保持了持久的CR[完整的回應]在6個月後,6名患者中有2名在12個月的掃描中保持長期CR,並繼續接受試驗。基於這一消息,Cariou的股價在同一天下跌了9%以上。
If you are a shareholder who suffered a loss, click here to participate.
如果您是蒙受損失的股東,請單擊此處參與。
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at , or by email at bschall@schallfirm.com.
我們還鼓勵您聯繫Schall律師事務所的Brian Schall,1880世紀公園東區,404Suite404,洛杉磯,CA 90067,電話:310301-3335,討論您的免費權利。您也可以通過公司的網站或電子郵件bschall@schallffer.com聯繫我們。
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
本案中的課程尚未獲得認證,在獲得認證之前,您不會由律師代表。如果你選擇不採取行動,你可以保持缺席班級成員的身分。
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
Schall律師事務所代表世界各地的投資者,專門處理證券集體訴訟和股東權利訴訟。
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
根據適用的法律和道德規則,本新聞稿在某些司法管轄區可能被視為律師廣告。
CONTACT:
聯繫方式:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
沙爾律師事務所
布萊恩·舒爾,Esq.
310-301-3335
郵箱:Info@schallFirm.com
To view the source version of this press release, please visit
要查看本新聞稿的源版本,請訪問
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧